Literature DB >> 30429953

Synthesis of Cyanoenone-Modified Diterpenoid Analogs as Novel Bmi-1-Mediated Antitumor Agents.

Lian-Fang Yang1, Yajing Xing2, Jie-Xin Xiao1, Jia Xie2, Wei Gao1, Jiuqing Xie2, Li-Ting Wang1, Jinhua Wang2, Mingyao Liu2, Zhengfang Yi2, Wen-Wei Qiu1.   

Abstract

Bmi-1 is overexpressed in colorectal cancer (CRC) and served as a novel therapeutic target for the treatment of CRC. A series of novel cyanoenone-modified diterpenoid analogs was synthesized and investigated for their antiproliferative activity against CRC cells. The results showed that most of these compounds exhibited potent antiproliferative and Bmi-1 inhibitory activity. Among them, the most active compound 33 (SH498) showed more potent antiproliferative activity than the positive control compound PTC-209. These synthetic diterpenoid analogs were less toxic for normal human fibroblasts (HAF) than for CRC cells. Especially 33, its selectivity index (SI) between HAF and tumor cells was 7.3-13.1, which was much better than PTC-209. The polycomb repressive complex 1 (PRC1) complex, transwell migration, colony formation, cancer stem cell proliferation, and apoptosis assays of 33 were performed on CRC cell lines. The in vivo antitumor effect of 33 was also observed in HCT116 tumor-bearing mice.

Entities:  

Year:  2018        PMID: 30429953      PMCID: PMC6231181          DOI: 10.1021/acsmedchemlett.8b00345

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  31 in total

1.  The BMI1 polycomb protein represses cyclin G2-induced autophagy to support proliferation in chronic myeloid leukemia cells.

Authors:  L Mourgues; V Imbert; M Nebout; P Colosetti; Z Neffati; P Lagadec; E Verhoeyen; C Peng; E Duprez; L Legros; N Rochet; V Maguer-Satta; F-E Nicolini; D Mary; J-F Peyron
Journal:  Leukemia       Date:  2015-04-30       Impact factor: 11.528

2.  The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute myeloid leukemia cells.

Authors:  M Konopleva; R Contractor; S M Kurinna; W Chen; M Andreeff; P P Ruvolo
Journal:  Leukemia       Date:  2005-08       Impact factor: 11.528

3.  BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer.

Authors:  Nitu Bansal; Monica Bartucci; Shamila Yusuff; Stephani Davis; Kathleen Flaherty; Eric Huselid; Michele Patrizii; Daniel Jones; Liangxian Cao; Nadiya Sydorenko; Young-Choon Moon; Hua Zhong; Daniel J Medina; John Kerrigan; Mark N Stein; Isaac Y Kim; Thomas W Davis; Robert S DiPaola; Joseph R Bertino; Hatem E Sabaawy
Journal:  Clin Cancer Res       Date:  2016-06-15       Impact factor: 12.531

Review 4.  Oleanolic acid and its synthetic derivatives for the prevention and therapy of cancer: preclinical and clinical evidence.

Authors:  Muthu K Shanmugam; Xiaoyun Dai; Alan Prem Kumar; Benny K H Tan; Gautam Sethi; Anupam Bishayee
Journal:  Cancer Lett       Date:  2014-01-30       Impact factor: 8.679

Review 5.  Colorectal cancer.

Authors:  David Cunningham; Wendy Atkin; Heinz-Josef Lenz; Henry T Lynch; Bruce Minsky; Bernard Nordlinger; Naureen Starling
Journal:  Lancet       Date:  2010-03-20       Impact factor: 79.321

6.  Rapamycin, a mTOR inhibitor, induced growth inhibition in retinoblastoma Y79 cell via down-regulation of Bmi-1.

Authors:  Yan-Dong Wang; Yong-Jing Su; Jian-Ying Li; Xiang-Chao Yao; Guang-Jiang Liang
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

7.  Self-renewal as a therapeutic target in human colorectal cancer.

Authors:  Antonija Kreso; Peter van Galen; Nicholas M Pedley; Evelyne Lima-Fernandes; Catherine Frelin; Thomas Davis; Liangxian Cao; Ramil Baiazitov; Wu Du; Nadiya Sydorenko; Young-Choon Moon; Lianne Gibson; Yadong Wang; Cherry Leung; Norman N Iscove; Cheryl H Arrowsmith; Eva Szentgyorgyi; Steven Gallinger; John E Dick; Catherine A O'Brien
Journal:  Nat Med       Date:  2013-12-01       Impact factor: 53.440

8.  Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer.

Authors:  Bao-Hong Guo; Yan Feng; Rong Zhang; Li-Hua Xu; Man-Zhi Li; Hsiang-Fu Kung; Li-Bing Song; Mu-Sheng Zeng
Journal:  Mol Cancer       Date:  2011-01-28       Impact factor: 27.401

9.  A miR-200c/141-BMI1 autoregulatory loop regulates oncogenic activity of BMI1 in cancer cells.

Authors:  Manjari Dimri; Mingu Kang; Goberdhan P Dimri
Journal:  Oncotarget       Date:  2016-06-14

10.  Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment.

Authors:  Arnold Bolomsky; Karin Schlangen; Wolfgang Schreiner; Niklas Zojer; Heinz Ludwig
Journal:  J Hematol Oncol       Date:  2016-03-02       Impact factor: 17.388

View more
  3 in total

1.  d-Borneol enhances cisplatin sensitivity via p21/p27-mediated S-phase arrest and cell apoptosis in non-small cell lung cancer cells and a murine xenograft model.

Authors:  Jinxiu Li; Jianmei Yuan; Yong Li; Jian Wang; Daoyin Gong; Qian Xie; Rong Ma; Jiajun Wang; Mihong Ren; Danni Lu; Zhuo Xu
Journal:  Cell Mol Biol Lett       Date:  2022-07-26       Impact factor: 8.702

Review 2.  The Crucial Roles of Bmi-1 in Cancer: Implications in Pathogenesis, Metastasis, Drug Resistance, and Targeted Therapies.

Authors:  Jie Xu; Lin Li; Pengfei Shi; Hongjuan Cui; Liqun Yang
Journal:  Int J Mol Sci       Date:  2022-07-26       Impact factor: 6.208

3.  A Relay Strategy Actuates Pre-Existing Trisubstituted Olefins in Monoterpenoids for Cross-Metathesis with Trisubstituted Alkenes.

Authors:  Karim A Bahou; D Christopher Braddock; Adam G Meyer; G Paul Savage; Zhensheng Shi; Tianyou He
Journal:  J Org Chem       Date:  2020-03-19       Impact factor: 4.354

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.